Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury

Sponsor
University of Washington (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05267951
Collaborator
(none)
9
2
28

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.

Condition or Disease Intervention/Treatment Phase
  • Device: Open-loop Stimulation
  • Device: Close-loop Stimulation
  • Other: Functional Task Practice
N/A

Detailed Description

After being informed about the purpose, study timeline, and procedures, all participants giving written informed consent will undergo repeated baseline measurements throughout four weeks, followed by intensive exercise therapy for six weeks.

Next, participants will receive (1) closed-loop stimulation and (2) open-loop stimulation treatment for Aim 1 Section of the study. Stimulation will be delivered non-invasively using skin electrodes on the back of the neck. Each treatment arm will last six weeks. The investigators will determine the order of the treatment arms randomly. For closed-loop stimulation, The investigators will place a sensor on the arm muscles over the skin. This sensor will detect the movement and start the stimulation accordingly.

For Aim 2 Section, intervention arms will consist of (1) transcutaneous stimulation, followed by (2) spasticity-reducing stimulation treatment arms.

There will be a 6-week waiting period between two stimulation arms where participants will not receive any stimulation or exercise therapy. Treatments will last 90 minutes per session, three sessions per week. Overall participation in the study will last ten months: Four weeks baseline + three treatment periods (each will last six weeks) + six weeks waiting period between stimulation treatments + 12 weeks follow-up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
9 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Participants who participate in Aim 1 Section of the study will receive open-loop and closed-loop stimulation intervention arms in a randomized order. The order of the two interventions in the Aim 2 Section of the study will be the same for all participants enrolled in the Aim 2 Section of the study.Participants who participate in Aim 1 Section of the study will receive open-loop and closed-loop stimulation intervention arms in a randomized order. The order of the two interventions in the Aim 2 Section of the study will be the same for all participants enrolled in the Aim 2 Section of the study.
Masking:
Single (Outcomes Assessor)
Masking Description:
Functional measurements and all other assessments will be done by an examiner who does not know the order of the intervention arm.
Primary Purpose:
Treatment
Official Title:
Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Open-loop Stimulation

Continuous stimulation

Device: Open-loop Stimulation
Spinal cord stimulation will be applied continuously over the skin throughout the intervention session.

Other: Functional Task Practice
Exercise therapy consists of repeated functional hand and arm movements
Other Names:
  • Intensive exercise therapy
  • Experimental: Close-loop Stimulation

    Intended movement-based stimulation.

    Device: Close-loop Stimulation
    Spinal cord stimulation will start and stop based on the signals that come from the sensors placed on upper limb muscle surfaces.

    Other: Functional Task Practice
    Exercise therapy consists of repeated functional hand and arm movements
    Other Names:
  • Intensive exercise therapy
  • Outcome Measures

    Primary Outcome Measures

    1. Change from baseline- Graded Redefined Assessment of Strength, Sensation, and Prehension version 2 ["Repeated measurements once every two weeks throughout the study, an average of 10 months".]

      Measurement of upper limb strength, sensation, qualitative prehension, and quantitative prehension (range 0-188, higher score mean better outcome)

    2. Change from baseline- Capabilities of Upper Extremity Test ["Repeated measurements once every two weeks throughout the study, an average of 10 months".]

      Measures unilateral and bilateral hand and arm function (range 0-128, higher score mean better outcome)

    3. Change from baseline- Grip and Pinch Force ["Repeated measurements once every two weeks throughout the study, an average of 10 months".]

      Grip and pinch force measurement using a dynamometer (higher score mean better outcome)

    4. Change from baseline- Modified Ashworth Scale ["Repeated measurements once every two weeks throughout the study, an average of 10 months".]

      Clinician administered assessment of spasticity (range 0-4, lower score mean better outcome)

    Secondary Outcome Measures

    1. Change from baseline- International Standards for Neurologic Classification of Spinal Cord Injury - Motor Score ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Standard manual muscle strength examination (Range 0-100 points, higher score mean better outcome)

    2. Change from baseline- International Standards for Neurologic Classification of Spinal Cord Injury - Sensory Score ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Standard examination of dermatomal sensation (range 0-224 points, higher score mean better outcome)

    3. Change from baseline- International Standards of Autonomic Functions after Spinal Cord Injury ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Clinician assessment to document remaining autonomic functions after spinal cord injury

    4. Change from baseline- H-Reflex ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Electrophysiologic measurement of H-reflex (lower Hmax/Mmax ratio mean better outcome)

    5. Change from baseline- Somatosensory Evoked Potentials ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Electrophysiologic evaluation of sensory pathways between the brain and the limb (shorter latency mean better outcome)

    6. Change from baseline- Motor Evoked Potentials ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Electrophysiologic evaluation of motor pathways between the brain and the muscles (higher amplitude mean better outcome)

    7. Change from baseline Spinal Cord Independence Measure Self Report ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Quantification of the level of independence in daily activities (range 0-100 points, higher score mean better outcome)

    Other Outcome Measures

    1. Change from baseline- World Health Organization Quality of Life Questionnaire ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Self-reported questionnaire on quality of life (range 0-100 points, higher score mean better outcome)

    2. Change from baseline- Spinal Cord Injury - Functional Index Short-Form ["Baseline"/"At the end of each treatment arm"/"Through study completion"]

      Patient-reported questionnaire (range 0-100 points, higher score mean better outcome)

    3. Change from baseline- International Spinal Cord Injury Bowel Function Basic Data Set.v.2.1 ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Patient-reported questionnaire (range 0-47 points, lower score mean better outcome)

    4. Change from baseline- Patient Reported Impact of Spasticity Measure ["Repeated measurements once every eight weeks throughout the study, an average of 10 months".]

      Patient-reported questionnaire (range 0-164 points, lower score mean better outcome)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. has cervical (C8 or higher), incomplete (American Spinal Cord Injury Impairment Scale
    • C or D) traumatic spinal cord injury, minimum 1-year post-injury
    1. has difficulty with hand functions in activities of daily living (e.g., dressing, grooming, feeding)

    2. stable medical condition without cardiopulmonary disease or autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities

    3. capable of performing simple cued motor tasks

    4. has ability to attend intervention/functional task training and assessment sessions 3 times/week

    5. has adequate social support to participate in all intervention and baseline/follow-up assessment sessions throughout 40 weeks.

    6. has ability to read and speak English

    Exclusion Criteria:
    1. dependent on ventilation support

    2. has implanted stimulator (e.g., pacemaker, vagus nerve stimulator, cochlear implant, etc.) or baclofen pump

    3. has metallic devices and implants in the head (e.g., deep brain stimulators, aneurysm clips/coils, and stents, vagus nerve stimulators)

    4. has a history or current signs/symptoms of syringomyelia (progressive pain, muscle weakness, and/or sensory loss; deterioration of bowel/bladder function)

    5. has autoimmune etiology of spinal cord dysfunction/injury

    6. has received botulinum toxin injections in upper extremity muscles in the prior 6 months

    7. has tendon transfer or nerve transfer surgery in the upper extremity,

    8. taking tizanidine, dantrolene or diazepam

    9. has history of seizures or increased risk for seizures

    10. has history of chronic headaches or migraines

    11. has history of neurologic diseases, such as stroke, multiple sclerosis, traumatic brain injury, etc.

    12. has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.)

    13. has rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)

    14. has significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation

    15. has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention

    16. unhealed fracture, contracture, pressure sore, or frequent urinary tract infections or other illnesses that might interfere with upper extremity rehabilitation or testing activities

    17. has a history of severe allergy (i.e., allergic reaction that could not be treated with antihistaminic medication

    18. has alcohol and/or drug abuse (subject's verbal statement)

    19. has cancer

    20. pregnant (Childbearing potential will be asked at screening, baseline, and every subsequent visit in which the subject would receive transcutaneous spinal cord stimulation and/or Transcranial Magnetic Stimulation whether the participant could be pregnant. Pregnancy will be ruled out by an over-the-counter urine pregnancy test for all females of childbearing potential (1) at the time of enrollment, (2) prior to all sessions that include Transcranial Magnetic Stimulation, and also prior to the intervention phases of (3) closed-loop or (4) open-loop stimulation. Additional pregnancy tests may be performed if there is a concern of pregnancy.)

    21. lack of ability to fully comprehend, cooperate and/or safely perform study procedures in the investigator's opinion/judgment

    22. unable to read and/or comprehend the consent form

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Washington

    Investigators

    • Principal Investigator: Chet Moritz, Ph.D., University of Washington

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chet Moritz, Associate Professor: Division of Physical Therapy, University of Washington
    ClinicalTrials.gov Identifier:
    NCT05267951
    Other Study ID Numbers:
    • STUDY00013469
    First Posted:
    Mar 7, 2022
    Last Update Posted:
    Jul 26, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 26, 2022